Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).